Company Information

  

Address: 740 HEINZ AVENUE  
City: BERKELEY 
State: CA 
Zip Code: 94710 
Telephone: 510-848-4400 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

References herein to "we," "us," "Company", and "Aduro" refer to Aduro Biotech, Inc. and its consolidated subsidiaries unless the context specifically states otherwise. We are an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases, including cancer. We believe our three technology platforms are uniquely positioned to recruit and direct the immune system by activating cancer-fighting immune cells and inhibiting immune suppressive cells known to allow tumor growth. Product candidates from our LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes, STING Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies (i.e. chemotherapy and radiation) as well as other novel immunotherapies.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-1.36NAN/E
06/2017-1.58NAN/E
12/2016-1.40NAN/E
09/20161.01NA12.31
06/20162.08NA5.44
12/20150.88NA31.98

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.22Total Liab/Total Assets0.48
Net Inc/Total Assets-0.21Total Liab/Inv Cap0.52
Net Inc/Inv Cap-0.22Total Liab/Comm Equity0.50
Pretax Inc/Net Sales-1.37Interest Coverage RatioNA
Net Inc/Net Sales-1.80Curr Debt/EquityNA
Cash Flow/Net Sales-1.70LTD/EquityNA
SG&A/NetSales0.68Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover16.94Quick Ratio11.58
Inventory TurnoverNACurrent Ratio11.58
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work Cap0.16Inv/Curr AssetsNA
Net Sales/PP&E1.92  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 3.79 5.92 3.77 3.88
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 8.46 8.25 8.28 8.02
Operating Income -29.26 -23.90 -25.21 -25.14
Interest Exp NA NA NA NA
Pretax Income -28.39 -23.19 -24.56 -24.47
Other Income 0.87 0.72 0.65 -1.55
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -24.52 -19.40 -21.81 -29.57

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 345.51 377.24 353.96 347.43
Receivables - Total 13.86 3.43 1.05 1.14
Inventories - Total NA NA NA NA
Total Current Assets 363.96 384.96 360.92 354.76
Net Property, Plant & Equipment 28.28 26.36 26.44 26.38
Total Assets 465.13 463.56 435.49 438.61
Liabilities        
Accounts Payable 19.34 13.93 13.84 15.58
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 34.29 28.88 28.82 30.63
Long-Term Debt NA NA NA NA
Total Liabilities 208.72 205.82 206.48 211.39
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -257.73 -233.21 -213.81 -192.00
Treasury Stock NA NA NA NA
Total Stockholders' Equity 256.41 257.74 229.02 227.22
Total Liabilities and Stockholders' Equity 465.13 463.56 435.49 438.61

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -20.45 -21.27 -22.84 -25.53
Net Cash Provided by Investing Activities -22.98 54.62 36.98 -2.75
Net Cash Provided by Financing Activities 18.12 43.40 18.00 5.23

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.83-16.05--
12/201413.39-17.01--
12/201572.98-39.210.88
12/201650.68-91.15-1.40
Growth Rates294.10----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/179935,22045.56




Report Date : 12/4/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.